NCT04795869 2023-10-10Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell LymphomaNorthwestern UniversityPhase 2 Withdrawn
NCT01805037 2021-09-01Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasNorthwestern UniversityPhase 1/2 Terminated20 enrolled 17 charts